Praxis Precision Medicines
PRAX
About: Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Employees: 82
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
91% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 34
70% more call options, than puts
Call options by funds: $26.3M | Put options by funds: $15.5M
15% more capital invested
Capital invested by funds: $886M [Q1] → $1.02B (+$130M) [Q2]
2.66% more ownership
Funds ownership: 115.91% [Q1] → 118.57% (+2.66%) [Q2]
5% less funds holding
Funds holding: 149 [Q1] → 142 (-7) [Q2]
14% less funds holding in top 10
Funds holding in top 10: 7 [Q1] → 6 (-1) [Q2]
22% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 32
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
HC Wainwright & Co.
Douglas Tsao
|
$115
|
Buy
Maintained
|
5 Aug 2025 |
|
Chardan Capital
Rudy Li
|
$80
|
Buy
Maintained
|
29 Jul 2025 |
|
Oppenheimer
Jay Olson
|
$115
|
Outperform
Maintained
|
8 Jul 2025 |
Financial journalist opinion
Based on 15 articles about PRAX published over the past 30 days
